Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients

Journal of Biological Chemistry

Volumn 287, Issue 42, 2012, Pages 35484-35495

  Li, Jiang ^a   Mo, Hao Yuan ^a   Xiong, Geng ^a   Zhang, Lin ^a   He, Jia ^a   Huang, Zhou Feng ^a   Liu, Zhi Wei ^a   Chen, Qiu Yan ^a   Du, Zi Ming ^a   Zheng, Li Min ^a   Qian, Chao Nan ^a,b   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FUNCTIONS; CLINICAL OUTCOME; CLINICAL PROGNOSIS; CYTOKINES; EXPRESSION LEVELS; HEALTHY CONTROLS; IN-VITRO; INTERLEUKIN-17; MAMMALIAN TARGET; NASOPHARYNGEAL CARCINOMA; PATIENT PROGNOSIS; PERIPHERAL BLOOD; PROMOTING EFFECT; TUMOR CELLS; TUMOR MICROENVIRONMENT; TUMOR TISSUES;

BLOOD; CYTOLOGY; DISEASES; HISTOLOGY; MACROPHAGES; TISSUE CULTURE; TUMORS;

DIAGNOSIS;

CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; CXCL11 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MAMMALIAN TARGET OF RAPAMYCIN;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE MIGRATION; NASOPHARYNX; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TH17 CELL; TISSUE CULTURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT;

ADULT; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; RECEPTORS, CXCR4; SURVIVAL RATE; TH17 CELLS; TISSUE CULTURE TECHNIQUES; TUMOR MICROENVIRONMENT;

EID: 84867416852     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.367532     Document Type: Article

References (55)

1. Pathmanathan, R., Prasad, U., Chandrika, G., Sadler, R., Flynn, K., and Raab-Traub, N. (1995) Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am. J. Pathol. 146, 1355-1367
2. Cao, S. M., Simons, M. J., and Qian, C. N. (2011) The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 30, 114-119
3. Wee, J. T., Ha, T. C., Loong, S. L., and Qian, C. N. (2010) Is nasopharyngeal cancer really a "Cantonese cancer"? Chin. J. Cancer 29, 517-526
4. Niedobitek, G., Agathanggelou, A., and Nicholls, J. M. (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma. Viral gene expression, tumor cell phenotype, and the role of the lymphoid stroma. Semin. Cancer Biol. 7, 165-174 (Pubitemid 26395118)
5. Vasef, M. A., Ferlito, A., and Weiss, L. M. (1997) Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus. Ann. Otol. Rhinol. Laryngol. 106, 348-356 (Pubitemid 27175027)
6. Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011) Cancer immunoediting. Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570
7. Yu, H., Kortylewski, M., and Pardoll, D. (2007) Cross-talk between cancer and immune cells. Role of STAT3 in the tumor microenvironment. Nat. Rev. Immunol. 7, 41-51 (Pubitemid 46020826)
8. Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., and Yu, H. (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464
9. Lv, L., Pan, K., Li, X. D., She, K. L., Zhao, J. J., Wang, W., Chen, J. G., Chen, Y. B., Yun, J. P., and Xia, J. C. (2011) The accumulation and prognosis value of tumor-infiltrating IL-17-producing cells in esophageal squamous cell carcinoma. PLoS One 6, e18219
10. Zhang, J. P., Yan, J., Xu, J., Pang, X. H., Chen, M. S., Li, L., Wu, C., Li, S. P., and Zheng, L. (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50, 980-989
11. Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., Chang, A., Coukos, G., Liu, R., and Zou, W. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114, 1141-1149
12. Dürr, C., Pfeifer, D., Claus, R., Schmitt-Graeff, A., Gerlach, U. V., Graeser, R., Krüger, S., Gerbitz, A., Negrin, R. S., Finke, J., and Zeiser, R. (2010) CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 70, 10170-10181
13. + regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 6, e19495
14. Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., and Peng, G. (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J. Immunol. 184, 1630-1641
15. Zhang, Y. L., Li, J., Mo, H. Y., Qiu, F., Zheng, L. M., Qian, C. N., and Zeng, Y. X. (2010) Different subsets of tumor-infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 9, 4
16. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., and Rosenberg, S. A. (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342 (Pubitemid 36858717)
17. Deleted in proof
18. Kopf, H., de la Rosa, G. M., Howard, O. M., and Chen, X. (2007) Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int. Immunopharmacol. 7, 1819-1824 (Pubitemid 350046435)
19. Baribaud, F., Edwards, T. G., Sharron, M., Brelot, A., Heveker, N., Price, K., Mortari, F., Alizon, M., Tsang, M., and Doms, R. W. (2001) Antigenically distinct conformations of CXCR4. J. Virol. 75, 8957-8967 (Pubitemid 32851900)
20. Wee, A., Teh, M., and Raju, G. C. (1994) Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J. Clin. Pathol. 47, 453-456 (Pubitemid 24183934)
21. The Selected Cancers Cooperative Study Group (1990) The association of selected cancers with service in the United States military in Vietnam. III. Hodgkin disease, nasal cancer, nasopharyngeal cancer, and primary liver cancer. Arch. Intern. Med. 150, 2495-2505
22. + regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 101, 1947-1954
23. + IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 105, 15505-15510
24. + regulatory T cells in a murine model of pancreas cancer. J. Immunother. 32, 12-21
25. Shen, X., Li, N., Li, H., Zhang, T., Wang, F., and Li, Q. (2010) Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 136, 1745-1754
26. Addis, M. F., Tanca, A., Pagnozzi, D., Crobu, S., Fanciulli, G., Cossu- Rocca, P., and Uzzau, S. (2009) Generation of high quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics 9, 3815-3823
27. Stojanović, I., Cvjetićanin, T., Lazaroski, S., Stosić-Grujicić, S., and Miljković, D. (2009) Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology 126, 74-83
28. Harris, T. J., Grosso, J. F., Yen, H. R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., Housseau, F., Yu, H., Pardoll, D. M., and Drake, C. G. (2007) Cutting edge. An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J. Immunol. 179, 4313-4317
29. Delgoffe, G. M., Kole, T. P., Zheng, Y., Zarek, P. E., Matthews, K. L., Xiao, B., Worley, P. F., Kozma, S. C., and Powell, J. D. (2009) The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832-844
30. + T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J. Immunol. 184, 764-774
31. + T cell proliferation under hypoxia. J. Immunol. 186, 764-774
32. Schober, A., Bernhagen, J., and Weber, C. (2008) Chemokine-like functions of MIF in atherosclerosis. J. Mol. Med. 86, 761-770
33. + regulatory T cells. J. Immunol. 180, 122-129
34. Swann, J. B., Vesely, M. D., Silva, A., Sharkey, J., Akira, S., Schreiber, R. D., and Smyth, M. J. (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 105, 652-656 (Pubitemid 351171763)
35. Wang, C., Kang, S. G., Lee, J., Sun, Z., and Kim, C. H. (2009) The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol. 2, 173-183
36. Liu, J., Duan, Y., Cheng, X., Chen, X., Xie, W., Long, H., Lin, Z., and Zhu, B. (2011) IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem. Biophys. Res. Commun. 407, 348-354
37. Ratajczak, P., Janin, A., Peffault de Latour, R., Leboeuf, C., Desveaux, A., Keyvanfar, K., Robin, M., Clave, E., Douay, C., Quinquenel, A., Pichereau, C., Bertheau, P., Mary, J. Y., and Socié, G. (2010) Th17/Treg ratio in human graft-versus-host disease. Blood 116, 1165-1171
38. Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W. H., Pagès, F., and Galon, J. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, and th17) in patients with colorectal cancer. Cancer Res. 71, 1263-1271
39. Zhang, Y. L., Li, J., Mo, H. Y., Qiu, F., Zheng, L. M., Qian, C. N., and Zeng, Y. X. (2010) Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 9, 4
40. Zou, W., and Restifo, N. P. (2010) T(H)17 cells in tumor immunity and immunotherapy. Nat. Rev. Immunol. 10, 248-256
41. Evans, H. G., Gullick, N. J., Kelly, S., Pitzalis, C., Lord, G. M., Kirkham, B. W., and Taams, L. S. (2009) In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc. Natl. Acad. Sci. U.S.A. 106, 6232-6237
42. Kimura, A., Naka, T., and Kishimoto, T. (2007) IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. U.S.A. 104, 12099-12104 (Pubitemid 47185636)
43. Paintlia, M. K., Paintlia, A. S., Singh, A. K., and Singh, I. (2011) Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J. Neurochem. 116, 508-521
44. + T cells in malignant pleural effusion. J. Immunol. 185, 6348-6354
45. + T cell recruitment. J. Immunol. 182, 6907-6914
46. Bachand, A. M., Mundt, K. A., Mundt, D. J., and Montgomery, R. R. (2010) Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer. A meta-analysis. Crit. Rev. Toxicol. 40, 85-100
47. Chuang, C. C., Chuang, Y. C., Chang, W. T., Chen, C. C., Hor, L. I., Huang, A. M., Choi, P. C., Wang, C. Y., Tseng, P. C., and Lin, C. F. (2010) Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-κB activation during Vibrio vulnificus infection. BMC Immunol. 11, 50
48. Chen, Y. C., Zhang, X. W., Niu, X. H., Xin, D. Q., Zhao, W. P., Na, Y. Q., and Mao, Z. B. (2010) Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene 29, 3067-3078
49. Krockenberger, M., Engel, J. B., Kolb, J., Dombrowsky, Y., Häusler, S. F., Kohrenhagen, N., Dietl, J., Wischhusen, J., and Honig, A. (2010) Macrophage migration inhibitory factor expression in cervical cancer. J. Cancer Res. Clin. Oncol. 136, 651-657
50. Tarnowski, M., Grymula, K., Liu, R., Tarnowska, J., Drukala, J., Ratajczak, J., Mitchell, R. A., Ratajczak, M. Z., and Kucia, M. (2010) Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors, and inhibits recruitment of cancer-associated fibroblasts. Mol. Cancer Res. 8, 1328-1343
51. Fang, W., Li, X., Jiang, Q., Liu, Z., Yang, H., Wang, S., Xie, S., Liu, Q., Liu, T., Huang, J., Xie, W., Li, Z., Zhao, Y., Wang, E., Marincola, F. M., and Yao, K. (2008) Transcriptional patterns, biomarkers, and pathways characterizing nasopharyngeal carcinoma of Southern China. J. Transl. Med. 6, 32
52. Liao, B., Zhong, B. L., Li, Z., Tian, X. Y., Li, Y., and Li, B. (2010) Macrophage migration inhibitory factor contributes angiogenesis by up-regulating IL-8 and correlates with poor prognosis of patients with primary nasopharyngeal carcinoma. J. Surg. Oncol. 102, 844-851
53. Nishihira, J., Ishibashi, T., Fukushima, T., Sun, B., Sato, Y., and Todo, S. (2003) Macrophage migration inhibitory factor (MIF). Its potential role in tumor growth and tumor-associated angiogenesis. Ann. N.Y. Acad. Sci. 995, 171-182 (Pubitemid 36706624)
54. Takahashi, N., Nishihira, J., Sato, Y., Kondo, M., Ogawa, H., Ohshima, T., Une, Y., and Todo, S. (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol. Med. 4, 707-714 (Pubitemid 29051376)
55. Xia, H. H., Yang, Y., Chu, K. M., Gu, Q., Zhang, Y. Y., He, H., Wong, W. M., Leung, S. Y., Yuen, S. T., Yuen, M. F., Chan, A. O., and Wong, B. C. (2009) Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 115, 5441-5449